Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06123936
Other study ID # APHP220090
Secondary ID N° IDRCB: 2022-A
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2023
Est. completion date February 28, 2025

Study information

Verified date November 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Sonia MAKHLOUF
Phone 0145213010
Email sonia.makhlouf@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a clinical trial designed to assess the impact on influenza vaccination rates among people aged over 65 of a telephone text message recalling them to be vaccinated by their GP. Twenty-two GPs will be randomly selected in each arm (recall versus usual care, 1:1). Each GP will include a maximum of 210 patients by random selection from their patient list. A difference of 4 percentage points is expected between the two arms at the end vaccination campaign in the vaccination rate.


Description:

This is an open-label trial with 2 arms: an interventional or "recall" arm and a "usual care" or control arm. Cluster randomization at the physician level was chosen to avoid contamination within the same patients group. Physicians will be randomized at the start of the vaccination campaign in one of the two arms (1:1), and all patients eligible (with a maximum of 210 per doctor) to be vaccinated will be recalled or not, depending on their GPs arm.


Recruitment information / eligibility

Status Recruiting
Enrollment 8400
Est. completion date February 28, 2025
Est. primary completion date October 30, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: The inclusion criteria for physicians are: - To be a GPs - To be based in Ile-de-France (Paris region, France) - To be a user of the Eo medical software The patients inclusion criteria are: - belonging to the list of attending physicians of the participating GPs - being 65 years of age or older - having a medical file in the GP's Eo medical software - having been selected at random if the number of patients aged 65 or over exceeds 210 patients (for 44 participating GPs). Exclusion Criteria: - Patients for which their attending physicians considers participating inappropriate (e.g. palliative care)

Study Design


Intervention

Other:
Reminder
At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit. The type of recall and the date of it will be notified in the medical file of each patient.

Locations

Country Name City State
France Cabinet medical Lahire (01) Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The influenza vaccination rate will be calculated as the ratio between the number of patients vaccinated (those who will report having been vaccinated in the questionnaire send at the end of the campaign) and the number of patients aged 65 years and over The influenza vaccination rate will be calculated as the ratio between the number of patients vaccinated (i.e., those who will report having been vaccinated during the vaccination campaign in the questionnaire send at the end of the campaign) and the number of patients aged 65 years and over. 12 months
Secondary 1/ Social inequalities related to the intervention, based on individual and ecological indicators (social deprivation index for example) will be estimated via absolute indicators (SII: slope of the inequality index) and relative (RII: relative inequality At the end of the vaccination campaign, the GPs will send patients a postal mail containing: an accompanying explanatory letter, the patient questionnaire, and a pre-addressed and prepaid envelope for the return of the completed questionnaire to their attending physician. 1 year
Secondary 2/ Acceptability of reminders (in the intervention arm only) based on the description of the patients answers to the related question in the questionnaires. This outcome is assessed by questionnaire. At the end of the vaccination campaign, the GPs will send patients a postal mail containing: an accompanying explanatory letter, the patient questionnaire, and a pre-addressed and prepaid envelope for the return of the completed questionnaire to their attending physician. 1 year
Secondary 3/ Reasons for non-vaccination will be described (stratified by trial arm) based on the description of the patients answers to the related question in the questionnaires.This outcome is assessed by questionnaire. Reasons for non-vaccination will be described (stratified by trial arm) based on the description of the patients answers to the related question in the questionnaires. 1 year
Secondary 4/ Characteristics of participating GPs based on the description of the physicians answers to the related question in the questionnaires. These outcomes are assessed by the physician questionnaire. At the beginning of the study, participating GPs will answer a short questionnaire about their main characteristics (Sex, Date of birth, Size of the patients list...). 1 year
See also
  Status Clinical Trial Phase
Completed NCT05869201 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Phase 2/Phase 3
Completed NCT02103023 - Intradermal Influenza Vaccine in the Young Phase 3
Completed NCT05234229 - Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
Completed NCT04623047 - Infection Watch Study
Not yet recruiting NCT02465190 - Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa N/A
Completed NCT05620953 - Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
Recruiting NCT05739474 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children Phase 3
Active, not recruiting NCT05794412 - Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
Recruiting NCT05557539 - Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach N/A
Completed NCT03813966 - Nasal Swab Home Collection Kit (NSHC Kit) Study
Terminated NCT05105191 - Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room N/A
Not yet recruiting NCT06247059 - Reducing Respiratory Virus Transmission in Bangladeshi Classrooms N/A
Not yet recruiting NCT06175468 - Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease Phase 3
Active, not recruiting NCT01666782 - Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy Phase 2
Completed NCT05507567 - Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model Phase 2
Active, not recruiting NCT04998344 - An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh Phase 4